Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients

International Journal of Clinical Oncology

Volumn 18, Issue 1, 2013, Pages 38-45

  Kanda, Tatsuo ^a   Nishida, Toshirou ^b   Wada, Norihito ^c   Kobayashi, Osamu ^d   Yamamoto, Masakazu ^e   Sawaki, Akira ^f   Boku, Narikazu ^g   Koseki, Masato ^h   Doi, Toshihiko ⁱ   Toh, Yasushi ^j   Kakeji, Yoshihiro ^k   Sugiyama, Toshiro ^l   Komatsu, Yoshito ^m   Kikuchi, Shojiro ⁿ   Ogoshi, Kyoji ^o   Katai, Hitoshi ^p   Miyachi, Kazuhito ^q   Hirota, Seiichi ^r   Ohtsu, Atsushi ⁱ  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

^c KEIO UNIVERSITY HOSPITAL   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g SHIZUOKA CANCER CENTER   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION   (Japan)

ⁱ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^j NATIONAL KYUSHU CANCER CENTER   (Japan)

^k KYUSHU UNIVERSITY HOSPITAL   (Japan)

^l TOYAMA UNIVERSITY HOSPITAL   (Japan)

^m HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

ⁿ KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^o TOKAI UNIVERSITY HOSPITAL   (Japan)

^p NATIONAL CANCER CENTER HOSPITAL   (Japan)

^q DOKKYO MEDICAL UNIVERSITY   (Japan)

^r HYOGO COLLEGE OF MEDICINE   (Japan)

more..

Author keywords

Adjuvant therapy; Clinical trial; Gastrointestinal stromal tumor; GIST; Imatinib

Indexed keywords

CONTRAST MEDIUM; IMATINIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; EOSINOPHILIA; EYELID EDEMA; FACE EDEMA; FEMALE; GASTROINTESTINAL TUMOR; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SOMATIC MUTATION; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG TOXICITY; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PIPERAZINES; POSTOPERATIVE PERIOD; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECURRENCE; TREATMENT OUTCOME;

EID: 84874051023     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0339-7     Document Type: Article

References (19)

1. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human. Science 279:577-580
2. DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58
3. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
4. Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 8(Suppl 2):S1-S41
5. Kato H, Ichinose Y, Ohta M et al (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721
6. Romond EH, Perez EA, Bryant J et al (2005) Trastumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
7. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820
8. DeMatteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104
9. Nishida T, Shirao K, Sawaki A et al (2008) Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 13:244-251
10. Fletcher CDM, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459-465
11. Jovanovic BD, Levy PS (1997) A look at the rule of three. Am Stat 51:137-139
12. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70-83
13. Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349
14. van Oosteron AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 358:1421-1423
15. Takahashi T, Nakajima K, Nishitani A et al (2007) An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 12:369-374
16. LeCesne A, Ray-Coquard I, Bui BN et al (2010) Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomized phase 3 trial. Lancet Oncol 11:942-949
17. Rutkowski P, Nowecki Z, Nyckowski P et al (2006) Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93:304-311
18. Casali PG, Blay JY (2010) Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5):v98-v102
19. Kubota T (2006) Gastrointestinal stromal tumor (GIST) and imatinib. Int J Clin Oncol 11:184-189